ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för nelfinavir mesylate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar

Bibliografisk träff 2013-01-01

Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure studies).

National Toxicology Program.

Natl Toxicol Program Tech Rep Ser · technical report; journal article

Bibliografisk träff 2011-02-24

LC, LC-MS/TOF and MS(n) studies for the identification and characterization of degradation products of nelfinavir mesylate.

Tiwari RN, Bonde CG.

J Pharm Biomed Anal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jpba.2011.02.020

Bibliografisk träff 2010-03-30

Stress degradation studies of nelfinavir mesylate by Fourier transform infrared spectroscopy.

Singh P, Mehrotra R, Bakhshi AK.

J Pharm Biomed Anal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jpba.2010.03.030

Bibliografisk träff 2009-08-06

Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.

Pozniak A, Müller L, Salgo M, Jones JK, Larson P, Tweats D.

AIDS Res Ther · research-article; journal article · DOI 10.1186/1742-6405-6-18

Bibliografisk träff 2009-04-10

Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.

Müller L, Gocke E, Lavé T, Pfister T.

Toxicol Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.toxlet.2009.04.003

Bibliografisk träff 2008-02-01

Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.

Rebiere H, Maggio AF, Gimeno P, Levaillant D, Civade C, Bonnet PA, Tissier MH.

Pharmeur Sci Notes · journal article

Bibliografisk träff 2006-11-01

Evaluation of an International Pharmacopoeia method for the analysis of nelfinavir mesilate by liquid chromatography.

Yekkala RS, Vandenwayenberg S, Hoogmartens J, Adams E.

J Chromatogr A · research support, non-u.s. gov't; journal article · DOI 10.1016/j.chroma.2006.08.054

Bibliografisk träff 2006-03-20

Determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form by stability indicating HPLC.

Jing Q, Shen Y, Tang Y, Ren F, Yu X, Hou Z.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2006.02.003

Bibliografisk träff 2005-10-01

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.

Antimicrob Agents Chemother · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.49.10.4386-4389.2005

Bibliografisk träff 2000-12-01

Long-term stability of nelfinavir mesylate in human plasma.

Turner ML, Acosta EP.

Clin Chem · letter · DOI 10.1093/clinchem/46.12.2019

Bibliografisk träff 2000-03-01

Decrease in methodone levels with nelfinavir mesylate.

McCance-Katz EF, Farber S, Selwyn PA, O'Connor A.

Am J Psychiatry · letter; case reports · DOI 10.1176/appi.ajp.157.3.481

Bibliografisk träff 1999-05-01

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y.

Clin Infect Dis · clinical trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1086/514759

Bibliografisk träff 1998-06-01

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, Chapman S, Patick A, Hendricks A, Yuen GJ, Hoskins W, Clendeninn N, Ho DD.

J Infect Dis · clinical trial, phase ii; clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1086/515312

Bibliografisk träff 1997-11-01

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH.

J Med Chem · journal article · DOI 10.1021/jm9704098